Payment overview · 2025
General Payments
$1,259.87
72 reported records · 19 companies
Healthcare provider profile · identity verified
Constantine Khalil Saadeh, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · AMARILLO, TX · NPI 1457322869
Verified facts
What the public records show
CMS Open Payments records show Constantine Khalil Saadeh, M.D. received $1,259.87 in general payments during 2025 across 72 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Enbrel, Nucala, Orencia, Otezla, Tavneos.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Rinvoq by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Enbrel by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TAVNEOS as an associated drug or biological on 21404 records involving 7606 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Tavneos by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Symbicort by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Privigen as an associated drug or biological on 464 records involving 289 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Privigen by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORENCIA as an associated drug or biological on 10404 records involving 2463 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Orencia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nucala by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 350 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XOLAIR as an associated drug or biological on 5293 records involving 2861 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xolair by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $314.13 | 24.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $283.21 | 22.5% | 40 | 2025 |
| Blueprint Medicines Corporation | Unresolved — no canonical attribution shown | $102.14 | 8.1% | 4 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $66.47 | 5.3% | 2 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $62.31 | 5.0% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $61.47 | 4.9% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $52.79 | 4.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.80 | 4.0% | 2 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $48.65 | 3.9% | 2 | 2025 |
| TerSera Therapeutics LLC | Unresolved — no canonical attribution shown | $37.76 | 3.0% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $32.43 | 2.6% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $23.09 | 1.8% | 1 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $21.75 | 1.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.54 | 1.7% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.33 | 1.7% | 1 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $16.38 | 1.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.72 | 1.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.39 | 1.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.51 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,259.87 | 72 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $383.86 | 15 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $268.95 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $246.51 | 1 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $246.51 | 1 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Drug | Blueprint Medicines Corporation | $102.14 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $87.87 | 13 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $64.63 | 7 | 2025 |
Source payment records
|
|||||
| DAWNZERA Normalized: dawnzera |
Drug | Ionis Pharmaceuticals, Inc. | $62.31 | 2 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $52.79 | 3 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $50.80 | 2 | 2025 |
Source payment records
|
|||||
| Andembry Normalized: andembry |
Biological | CSL Behring | $48.65 | 2 | 2025 |
Source payment records
|
|||||
| Quzyttir Normalized: quzyttir |
Drug | TerSera Therapeutics LLC | $37.76 | 2 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $35.11 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $32.43 | 1 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols USA, LLC | $26.36 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $24.78 | 5 | 2025 |
Source payment records
|
|||||
| HADLIMA Normalized: hadlima |
Drug | Organon LLC | $23.09 | 1 | 2025 |
Source payment records
|
|||||
| DUROLANE Normalized: durolane |
Device | Bioventus LLC | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| Kineret Normalized: kineret |
Drug | SOBI, INC | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| NEMLUVIO Normalized: nemluvio |
Drug | Galderma Laboratories, L.P. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| Rhapsido Normalized: rhapsido |
Drug | Novartis Pharmaceuticals Corporation | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $9.86 | 2 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $6.61 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $3.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENBREL enbrel |
2025 | Enbrel | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUCALA nucala |
2025 | Nucala | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ORENCIA orencia |
2025 | Orencia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 61 | exact normalized | Medicare Part D |
| TAVNEOS tavneos |
2025 | Tavneos | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
53 | 16 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | TAVNEOS open payments reported associated product |
CMS Open Payments — General Payments 21404 supporting records · 7606 recipient NPIs · example record 1226871817 |
Tavneos · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
99 | 27 |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Privigen open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 289 recipient NPIs · example record 1232339064 |
Privigen · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ORENCIA open payments reported associated product |
CMS Open Payments — General Payments 10404 supporting records · 2463 recipient NPIs · example record 1184378623 |
Orencia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
350 | 87 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | XOLAIR open payments reported associated product |
CMS Open Payments — General Payments 5293 supporting records · 2861 recipient NPIs · example record 1200005083 |
Xolair · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 673 | 97 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 644 | 169 |
| Montelukast Sodium | Montelukast Sodium | 417 | 112 |
| Methotrexate | Methotrexate Sodium | 365 | 122 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 350 | 87 |
| Famotidine | Famotidine | 341 | 84 |
| Gabapentin | Gabapentin | 255 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 208 | 100 |
| Prednisone | Prednisone | 195 | 52 |
| Leflunomide | Leflunomide | 164 | 57 |
| Fluticasone Propionate | Fluticasone Propionate | 152 | 58 |
| Folic Acid | Folic Acid | 133 | 41 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 127 | 28 |
| Tramadol Hcl | Tramadol Hcl | 117 | 36 |
| Sulfasalazine | Sulfasalazine | 116 | 34 |
| Spiriva Respimat | Tiotropium Bromide | 113 | 28 |
| Allopurinol | Allopurinol | 104 | 22 |
| Breo Ellipta | Fluticasone/Vilanterol | 101 | 26 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 100 | 30 |
| Symbicort | Budesonide/Formoterol Fumarate | 99 | 27 |
| Epinephrine | Epinephrine | 95 | 78 |
| Potassium Chloride | Potassium Chloride | 95 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 94 | 35 |
| Enbrel Sureclick | Etanercept | 84 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 75 | 25 |
| Pilocarpine Hcl | Pilocarpine Hcl | 69 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 21 |
| Otezla | Apremilast | 61 | 12 |
| Azelastine Hcl | Azelastine Hcl | 59 | 23 |
| Omeprazole | Omeprazole | 59 | 17 |
| Pregabalin | Pregabalin | 59 | 20 |
| Furosemide | Furosemide | 57 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 54 | suppressed |
| Rinvoq | Upadacitinib | 53 | 16 |
| Azathioprine | Azathioprine | 51 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 18 |
| Alendronate Sodium | Alendronate Sodium | 49 | 14 |
| Meloxicam | Meloxicam | 49 | 19 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 47 | 12 |
| Alprazolam | Alprazolam | 43 | suppressed |
| Humira(Cf) Pen | Adalimumab | 43 | suppressed |
| Celecoxib | Celecoxib | 41 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 17 |
| Azithromycin | Azithromycin | 38 | 24 |
| Dulera | Mometasone/Formoterol | 38 | 11 |
| Sulfasalazine Dr | Sulfasalazine | 36 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 35 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 35 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 35 | 17 |
| Otrexup | Methotrexate/Pf | 35 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 32 | 26 |
| Ipratropium Bromide | Ipratropium Bromide | 31 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | 12 |
| Orencia Clickject | Abatacept | 29 | 13 |
| Cefdinir | Cefdinir | 28 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 28 | 11 |
| Dupixent Pen | Dupilumab | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 15 |
| Lidocaine Hcl | Lidocaine Hcl | 26 | 21 |
| Nucala | Mepolizumab | 26 | suppressed |
| Tavneos | Avacopan | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 23 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 16 |
| Dupixent Syringe | Dupilumab | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 23 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 23 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Febuxostat | Febuxostat | 21 | suppressed |
| Methotrexate Sodium | Methotrexate Sodium/Pf | 20 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 20 | 11 |
| Actemra Actpen | Tocilizumab | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 17 |
| Ramelteon | Ramelteon | 19 | suppressed |
| Chloroquine Phosphate | Chloroquine Phosphate | 18 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Isoniazid | Isoniazid | 17 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Humira(Cf) | Adalimumab | 16 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Eliquis | Apixaban | 13 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Orencia | Abatacept | 13 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Cosentyx Sensoready Pen | Secukinumab | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Enbrel | Etanercept | 12 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Opsumit | Macitentan | 12 | suppressed |
| Rasuvo | Methotrexate/Pf | 12 | suppressed |
| Xolair | Omalizumab | 12 | suppressed |
| Asmanex | Mometasone Furoate | 11 | suppressed |
| Bosentan | Bosentan | 11 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,259.87 · 72 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AYVAKIT, Andembry, Bimzelx, DALVANCE, DAWNZERA, DUROLANE, ENBREL, EVENITY, FASENRA, HADLIMA, KRYSTEXXA, Kineret, NEMLUVIO, NUCALA, OFEV, ORENCIA, OTEZLA, PURIFIED CORTROPHIN GEL, Prolastin-C Liquid, Quzyttir, Rhapsido, SAPHNELO, TAVNEOS, TEPEZZA, TEZSPIRE, TREMFYA, Xembify | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Enbrel play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error